Mark J. Chicarelli

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS^G12C Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · ACS Medicinal Chemistry Letters · 2018 · 104 citations · Full text

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

James F. Blake, John J. Gaudino, Jason De Meese et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 39 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Biochemistry +6

Identification of a New Class of Glucokinase Activators through Structure-Based Design

Ronald J. Hinklin, Steven A. Boyd, Mark J. Chicarelli et al. · Journal of Medicinal Chemistry · 2013 · 32 citations · Full text

Protein Assembly, Glycobiology, Insulin Signaling +21

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

Kurtis D. Davies, Michael Humphries, Francis X. Sullivan et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2011 · 25 citations · Full text

Tumor Biology, Oncology, Single-agent Inhibition +15